Arrowhead Research Publishes White Paper on RNAi Delivery Technology Acquired from Roche

(Nanowerk News) Arrowhead Research Corporation, a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today announced the publication of a white paper providing an overview of its proprietary dynamic polyconjugate (DPC) technology for safe and effective delivery of siRNA. The white paper may be found on the Arrowhead website at
Safe and effective siRNA delivery has been a key challenge to the field of therapeutic RNAi. The DPC platform was developed over many years by scientists at Arrowhead's newly acquired Madison, Wisconsin research and development facility to overcome this challenge. The technology is a radical departure from the standard liposomal or lipid nanoparticle siRNA delivery systems used by the majority of RNAi therapeutics companies. It represents one of the most promising solutions to the delivery problem that has plagued the RNAi therapeutics field since its inception. The white paper traces the development of the DPC platform from initial work published in 2007, detailing the critical advances in chemistry and architecture that have occurred over the past four years and culminated in the demonstration of safe and effective delivery of siRNAs to hepatocytes and tumor cells in non-human primates.
"DPCs are elegant, customizable, and powerful new tools to solve the delivery challenge in RNAi and enable the creation of a large variety of new therapeutics," said Dr. Christopher Anzalone, President and Chief Executive Officer of Arrowhead. "Studies in non-human primates have shown that DPCs are highly effective and have safety margins well beyond those currently achievable by other systems. Moreover, the modular nature of DPC technology and its ability to optimize individual components within the same polymer provide the potential to target all types of cells. This unparalleled delivery solution complements Arrowhead's portfolio of advanced siRNA delivery solutions, positioning the company as a partner of choice for large biotech and pharmaceutical companies interested in creating RNAi therapeutics."
About Arrowhead Research Corporation
Arrowhead Research Corporation is a nanomedicine company developing innovative therapies at the interface of biology and nanoengineering to cure disease and improve human health. Arrowhead is a leader in delivering small RNAs for gene silencing, and has programs in anti-obesity therapeutics and regenerative medicine.
Source: Arrowhead (press release)
Subscribe to a free copy of one of our daily
Nanowerk Newsletter Email Digests
with a compilation of all of the day's news.
These articles might interest you as well: